This week we learn about new research linking a commonly used joint pain supplement to faster dementia progression, the potential role of a sugar molecule found in red meat in increasing type 2 diabetes risk, how age-related muscle loss may increase susceptibility to infections, and promising advances in blood-based testing to predict cognitive decline.
Are you part of a health or life extension research organization? Our coalition has grown to over 90 member groups, including 25 major US organizations and 16 major international groups. We hope your organization will be next! Check below to find a link to join our coalition quickly and easily.
All this and more this week. Join us as we move forward into another exciting month of incredible opportunities in this burgeoning and revolutionary field.
Edwina Rogers, CEO
Global Healthspan Policy Institute
Facebook
Twitter
LinkedIn
Pain supplement glucosamine linked to faster dementia progression
New research suggests that glucosamine, a widely used supplement for joint pain, may be associated with accelerated dementia progression and increased mortality, raising questions about its long-term safety for people with cognitive impairment.
Sugar molecule in beef and lamb may be linked to type 2 diabetes risk
Preliminary research presented at the European Association for the Study of Diabetes suggests that Neu5Gc, a sugar molecule found in red meat, may contribute to an increased risk of type 2 diabetes, offering new insights into the relationship between meat consumption and metabolic health.
Losing Muscle as You Age May Be Linked to a Higher Risk of Infection, According to Research
A large observational study involving approximately 458,000 participants found that age-related muscle loss was associated with a 34% higher risk of infection, highlighting another potential connection between maintaining muscle mass and healthy aging.
Estimating cognitive impairment risk, timing
Researchers have found that combining blood levels of the Alzheimer’s-related protein p-tau217 with APOE4 genetic status may improve predictions of both the likelihood and timing of cognitive impairment, potentially advancing personalized approaches to dementia risk assessment.
